Use Of Preferred Providers Among Biologic Outsourcers

In Q42019, ISR surveyed outsourcers of biologic API and outsourcers of biologic drug product to ask whether their company uses a preferred providers list of contract manufacturers for outsourced manufacturing. The data show the majority of respondents use preferred providers for both large molecule API (59%) and large molecule drug product manufacturing (61%). To learn more, follow the links to the Biologic API and the Biologic Drug Product report previews.